Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-02-06
Target enrollment:
Participant gender:
Summary
A multi-center, randomized, double-blind, parallel controlled Phase III clinical study to
evaluate the clinical efficacy and safety of MW032 and Xgeva® in patients with bone
metastases from solid tumors.